NYSEAMERICAN:PTN - Palatin Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.71 -0.01 (-1.39 %)
(As of 12/17/2018 01:41 PM ET)
Previous Close$0.72
Today's Range$0.71 - $0.73
52-Week Range$0.68 - $1.59
Volume17,786 shs
Average Volume1.50 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PTN
Previous SymbolNYSE:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees19
Outstanding Shares203,060,000
Market Cap$0.00
OptionableNot Optionable

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its quarterly earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $2.40 million. View Palatin Technologies' Earnings History.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release their next quarterly earnings announcement on Monday, February 11th 2019. View Earnings Estimates for Palatin Technologies.

What price target have analysts set for PTN?

2 analysts have issued 12 month price targets for Palatin Technologies' shares. Their predictions range from $3.00 to $5.00. On average, they expect Palatin Technologies' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 463.4% from the stock's current price. View Analyst Price Targets for Palatin Technologies.

What is the consensus analysts' recommendation for Palatin Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.

Has Palatin Technologies been receiving favorable news coverage?

News headlines about PTN stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Palatin Technologies earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest in November. As of November 30th, there was short interest totalling 15,476,543 shares, an increase of 0.9% from the November 15th total of 15,345,944 shares. Based on an average trading volume of 1,477,907 shares, the short-interest ratio is presently 10.5 days. Approximately 8.1% of the shares of the stock are sold short. View Palatin Technologies' Current Options Chain.

Who are some of Palatin Technologies' key competitors?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the folowing people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 64)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 56)
  • Mr. Stephen T. Wills CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 61)
  • Burns McClellan, VP of Investor Relations

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.31%), Vanguard Group Inc (4.38%), Acadian Asset Management LLC (1.53%), Ativo Capital Management LLC (0.64%), TIAA CREF Investment Management LLC (0.21%) and AQR Capital Management LLC (0.19%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.

Which institutional investors are selling Palatin Technologies stock?

PTN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Palatin Technologies.

Which institutional investors are buying Palatin Technologies stock?

PTN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, Citadel Advisors LLC, Ativo Capital Management LLC, TIAA CREF Investment Management LLC and Vanguard Group Inc. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.71.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is http://www.palatin.com/.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.


MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  491
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel